Nichi-Iko Pharmaceutical
As of the edition of 20 October 2026, Nichi-Iko Pharmaceutical runs 3 drugs, 2 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Family history
The records place 2 company names in this family.
- Sagent Pharmaceuticals Inc.: acquired in 2016; successor Nichi-Iko Pharmaceutical Co., Ltd.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 1 |
| Total | 3 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Famotidine | none listed | 2 |
| Daptomycin | none listed | 0 |
A route B row is one company at one target.
Where its trials are
- Infections: 1 trials led
- Lungs and airways: 1 trials led